Pfizer Inc. (NYSE:PFE) Shares Bought by Capital Advisors Inc. OK

Capital Advisors Inc. OK boosted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 1.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,413,472 shares of the biopharmaceutical company's stock after buying an additional 17,032 shares during the quarter. Capital Advisors Inc. OK's holdings in Pfizer were worth $35,817,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Brighton Jones LLC increased its stake in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC increased its position in Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after buying an additional 2,087 shares in the last quarter. Inceptionr LLC purchased a new position in Pfizer in the 4th quarter valued at about $229,000. Callan Family Office LLC purchased a new stake in Pfizer in the 4th quarter worth approximately $595,000. Finally, Bank Julius Baer & Co. Ltd Zurich boosted its stake in Pfizer by 14.8% in the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 574,748 shares of the biopharmaceutical company's stock worth $16,688,000 after buying an additional 74,090 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Down 0.6%

NYSE PFE traded down $0.15 on Monday, hitting $25.23. 34,892,825 shares of the stock traded hands, compared to its average volume of 41,695,591. The company has a market capitalization of $143.44 billion, a P/E ratio of 18.28, a price-to-earnings-growth ratio of 0.92 and a beta of 0.58. The stock has a 50-day moving average of $23.72 and a 200 day moving average of $24.81. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same period in the prior year, the company earned $0.82 earnings per share. The business's revenue was down 7.8% compared to the same quarter last year. As a group, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.82%. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on PFE shares. TD Cowen lowered their target price on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a report on Tuesday, April 22nd. Cantor Fitzgerald assumed coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target on the stock. Berenberg Bank dropped their price objective on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Thursday, May 29th. Guggenheim reissued a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Finally, Morgan Stanley upped their price target on Pfizer from $31.00 to $32.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $28.55.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.